Uncovering T cell trajectories in human cancer

揭示人类癌症中的 T 细胞轨迹

• 批准号: 463163
• 负责人: Ohashi Pamela S
• 金额: $ 69.66万
• 依托单位: Princess Margaret Cancer Centre (Toronto)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-03-01 至 2027-03-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=463163&lang=en
• 关键词: Cancer; Genomics; Immunology; Immunotherapy; Melanoma; Ovarian; Pd-1; T Cells; Tumor Infiltrating Lymphocytes

One population of white blood cells, called T cells, is known to have the ability to kill tumor cells. Clinical studies have shown that augmenting the function of these T cells using a particular antibody drug that targets a molecule called PD-1 is an ex

已知一种称为 T 细胞的白细胞具有杀死肿瘤细胞的能力。 临床研究表明，使用针对 PD-1 分子的特定抗体药物来增强这些 T 细胞的功能是一种有效的方法。